Update on prognostic markers for endometrial cancer

Pratibha S. Binder, David G. Mutch

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Endometrial cancer is the most common gynecologic cancer in the USA and the second most common worldwide after cervical cancer. While common symptomatology of endometrial cancer leads to early diagnosis and favorable 5-year survival in most cases, there is a subset of cancers that have a poorer prognosis. The clinical and pathologic prognostic factors for endometrial cancer are well known and instrumental in determining the need for adjuvant therapy. Recently, research has been focused on the identification of molecular changes leading to different histologic subtypes to improve classification of endometrial cancer. The identification of novel mutations and molecular profiles should enhance our ability to personalize adjuvant treatment with genome-guided targeted therapy.

Original languageEnglish
Pages (from-to)277-288
Number of pages12
JournalWomen's Health
Issue number3
StatePublished - May 2014


  • biologic markers
  • endometrial cancer
  • prognosis
  • targeted therapy


Dive into the research topics of 'Update on prognostic markers for endometrial cancer'. Together they form a unique fingerprint.

Cite this